However, the effects of SGLT-2 inhibitors on arrhythmia, especially AF, were only described by subgroup post-hoc analyses or meta-analyses, so they usually focused on the AF incidence rate and could not analyze other specific properties of AF [16,32,45]. The gene discussed is SLC5A2; the disease is atrial fibrillation.